Studies have shown that drugs, such as angiotensin receptor blockers [124]; prostaglandins [11]; and ACE [13,14], endothelin-1 [99], and PDE-5 inhibitors [12], have a positive impact on mortality and quality of life in patients with CHD. This evidence concerns the gene EDN1 and coronary artery disorder.